CureVac
Markus Kramer is a Senior Manager at CureVac, leading the team in Analytical Development. Prior to this role, Markus served as the Senior Scientist and Team Lead in Biophysical Chemistry at CureVac, focusing on analytical method development and drug product characterization for mRNA-based formulations. Before their time at CureVac, Markus worked as a Scientist in Early Process Development, specializing in lipid nanoparticle-based vaccines. Markus also has experience in operating accounting at the Institute for Organic Chemistry at the University of Stuttgart and as a chemical engineer at Universität Stuttgart. Markus holds a Ph.D. in Chemistry from the University of Stuttgart.
This person is not in any offices
CureVac
8 followers
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases.